BioMarin (BMRN) director receives 7,490 RSUs in stock grant

Rhea-AI Filing Summary

ANDERSON ELIZABETH M reported acquisition or exercise transactions in this Form 4 filing.

BioMarin Pharmaceutical director Elizabeth M. Anderson received a stock-based compensation grant. On June 2, 2026, she was awarded 7,490 shares of Common Stock in the form of restricted stock units at no cash cost, as the price is listed as not applicable.

After this grant, Anderson directly holds 41,940 shares of BioMarin Common Stock. This is a compensation-related award, not an open-market purchase or sale, and does not reflect a discretionary trading decision.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ANDERSON ELIZABETH M

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,490	$0.00	--

Holdings After Transaction: Common Stock — 41,940 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 7,490 shares Price per share: $0.0000 Shares held after grant: 41,940 shares +2 more

5 metrics

RSUs granted 7,490 shares Restricted stock units granted on June 2, 2026

Price per share $0.0000 Equity compensation grant, price not applicable

Shares held after grant 41,940 shares Total direct holdings following June 2, 2026 transaction

Transaction code A Grant, award, or other acquisition of Common Stock

Ownership type Direct (D) Direct ownership of BioMarin Common Stock after grant

Key Terms

Restricted stock units, Grant, award, or other acquisition, Common Stock

3 terms

Restricted stock units financial

"Restricted stock units granted on June 2, 2026. Price not applicable."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Grant, award, or other acquisition financial

"Transaction coded A as a grant, award, or other acquisition."

Common Stock financial

"The security involved in the transaction is BioMarin Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ANDERSON ELIZABETH M

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CALIFORNIA 94901

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		A		7,490	A	$0(1)	41,940	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units granted on June 2, 2026. Price not applicable.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BioMarin (BMRN) report for Elizabeth M. Anderson?

BioMarin reported that director Elizabeth M. Anderson received a grant of 7,490 restricted stock units on June 2, 2026. These units convert into Common Stock and are compensation-related, not an open-market trade, so they do not indicate a buy or sell decision.

How many BioMarin (BMRN) shares does Elizabeth M. Anderson hold after this grant?

After the June 2, 2026 restricted stock unit grant, Elizabeth M. Anderson directly holds 41,940 shares of BioMarin Common Stock. This total includes the 7,490 shares awarded in the reported transaction, reflecting her updated direct ownership position as disclosed.

Was cash paid for the 7,490 BioMarin (BMRN) shares granted to Elizabeth M. Anderson?

No cash was paid for these shares. The filing shows a price per share of 0.0000 and notes they are restricted stock units, with price not applicable. This indicates a non-cash equity compensation grant rather than an open-market purchase.

Is the BioMarin (BMRN) Form 4 transaction a purchase or sale of stock?

The Form 4 reports an acquisition through a grant or award, coded “A” for restricted stock units. It is classified as a grant or other acquisition, not an open-market purchase or sale, so it reflects compensation rather than trading activity in the market.

What does the restricted stock unit grant mean for BioMarin (BMRN) shareholders?

The grant modestly increases director Elizabeth M. Anderson’s equity stake through 7,490 restricted stock units. It aligns her interests with shareholders by tying compensation to BioMarin’s stock performance, but represents a routine governance practice rather than a major corporate or financial event.